Research Articles
Research articles concerning NAFLD are extracted from PubMed. For each individual article, related therapeutic strategies, targets, drugs and associated diseases in NAFLDkb are presented with knowledge graphs.
stats1
stats2
stats3
stats4
Search for:
Obeticholic Acid216 records.
| Article ID | PMID | Source | Title | Publish Year | |
|---|---|---|---|---|---|
| A15078 | 29107284 | Mol Metab | Superior reductions in hepatic steatosis and fibrosis with co-administration of a glucagon-like peptide-1 receptor agonist and obeticholic acid in mice. | 2017 | Details |
| A15097 | 29098111 | Liver Res | Bile acid receptors link nutrient sensing to metabolic regulation. | 2017 | Details |
| A15132 | 29082798 | Expert Rev Gastroenterol Hepatol | The use of obeticholic acid for the management of non-viral liver disease: current clinical practice and future perspectives. | 2017 | Details |
| A15716 | 28746779 | Liver Int | Hepatic farnesoid X receptor protein level and circulating fibroblast growth factor 19 concentration in children with NAFLD. | 2017 | Details |
| A15946 | 28641031 | Expert Opin Drug Saf | Treatment options for nonalcoholic steatohepatitis - a safety evaluation. | 2017 | Details |
| A15959 | 28637104 | Korean J Gastroenterol | [Treatment Options in Non-alcoholic Fatty Liver Disease]. | 2017 | Details |
| A15989 | 28624576 | Gastroenterology | Agreement Between Magnetic Resonance Imaging Proton Density Fat Fraction Measurements and Pathologist-Assigned Steatosis Grades of Liver Biopsies From Adults With Nonalcoholic Steatohepatitis. | 2017 | Details |
| A16267 | 28478385 | J Biol Chem | Farnesoid X receptor induces Takeda G-protein receptor 5 cross-talk to regulate bile acid synthesis and hepatic metabolism. | 2017 | Details |
| A16414 | 28406477 | Cell Death Dis | miR-21 ablation and obeticholic acid ameliorate nonalcoholic steatohepatitis in mice. | 2017 | Details |
| A16627 | 28276821 | Expert Rev Gastroenterol Hepatol | Current and future treatment options in non-alcoholic steatohepatitis (NASH). | 2017 | Details |
| A17047 | 28029021 | Endocrinol Metab (Seoul) | Bile Acid Nuclear Receptor Farnesoid X Receptor: Therapeutic Target for Nonalcoholic Fatty Liver Disease. | 2016 | Details |
| A17157 | 27942596 | JCI Insight | Development of an in vitro human liver system for interrogating nonalcoholic steatohepatitis. | 2016 | Details |
| A17161 | 27939613 | Toxicol In Vitro | Pharmacotoxicology of clinically-relevant concentrations of obeticholic acid in an organotypic human hepatocyte system. | 2016 | Details |
| A17238 | 27895393 | World J Gastroenterol | Emerging role of obeticholic acid in the management of nonalcoholic fatty liver disease. | 2016 | Details |
| A17592 | 27729634 | Clin Mol Hepatol | Non-alcoholic fatty liver diseases: update on the challenge of diagnosis and treatment. | 2016 | Details |
| A17595 | 27727520 | Liver Int | The therapeutic landscape of non-alcoholic steatohepatitis. | 2016 | Details |
| A17704 | 27646933 | Gut | Current and upcoming pharmacotherapy for non-alcoholic fatty liver disease. | 2016 | Details |
| A17814 | 27564402 | Expert Opin Pharmacother | Emerging and future therapies for nonalcoholic steatohepatitis in adults. | 2016 | Details |
| A17842 | 27543499 | Br Med Bull | Non-alcoholic fatty liver disease in 2016. | 2016 | Details |
| A17870 | 27512874 | Medicine (Baltimore) | Comparative efficacy of interventions on nonalcoholic fatty liver disease (NAFLD): A PRISMA-compliant systematic review and network meta-analysis. | 2016 | Details |
| A17895 | 27493105 | Ann Hepatol |  NASH: A glance at the landscape of pharmacological treatment. | 2017 | Details |
| A17923 | 27475255 | Biochim Biophys Acta | Bile acid receptor agonists INT747 and INT777 decrease oestrogen deficiency-related postmenopausal obesity and hepatic steatosis in mice. | 2016 | Details |
| A18085 | 30695468 | Rinsho Byori | [Progress in the Management of NAFLD/NASH]. | 2016 | Details |
| A18205 | 27287838 | Orv Hetil | [Non-alcoholic fatty liver disease and hepatocellular carcinoma - 2016]. | 2016 | Details |
| A18386 | 27170389 | Dig Dis | Non-Alcoholic Steatohepatitis: From Pathophysiology to Novel Therapies. | 2016 | Details |
| A18468 | 27109453 | Diabetes Obes Metab | Effects of obeticholic acid on lipoprotein metabolism in healthy volunteers. | 2016 | Details |
| A18671 | 27003143 | Dig Dis Sci | Novel Pharmacotherapy Options for NASH. | 2016 | Details |
| A18692 | 26997214 | Saudi J Gastroenterol | Treatment of nonalcoholic fatty liver disease: Where do we stand? an overview. | 2017 | Details |
| A18919 | 26870934 | Semin Liver Dis | Nuclear Receptor Modulation for the Treatment of Nonalcoholic Fatty Liver Disease. | 2016 | Details |
| A19029 | 26812075 | J Hepatol | Gene expression profiling in human precision cut liver slices in response to the FXR agonist obeticholic acid. | 2016 | Details |
| A19186 | 28670148 | Clin Med Insights Ther | Nonalcoholic Fatty Liver Disease: Epidemiology, Pathogenesis, Natural History, Diagnosis, and Current Treatment Options. | 2016 | Details |
| A19282 | 26655953 | J Biol Chem | Farnesoid X Receptor Protects against Kidney Injury in Uninephrectomized Obese Mice. | 2015 | Details |
| A19745 | 26378648 | Semin Liver Dis | Pharmacotherapy for Nonalcoholic Fatty Liver Disease. | 2015 | Details |
| A20055 | 26189925 | Hepatology | Comparative effectiveness of pharmacological interventions for nonalcoholic steatohepatitis: A systematic review and network meta-analysis. | 2015 | Details |
| A20168 | 26114083 | Curr Hepatol Rep | PATHOGENESIS OF HEPATOCELLULAR CARCINOMA DEVELOPMENT IN NON ALCOHOLIC FATTY LIVER DISEASE. | 2015 | Details |
| A20262 | 26057287 | JAMA | Nonalcoholic fatty liver disease: a systematic review. | 2015 | Details |
| A20272 | 26052375 | World J Hepatol | Pathophysiological mechanisms involved in non-alcoholic steatohepatitis and novel potential therapeutic targets. | 2015 | Details |
| A20584 | 25873078 | Exp Biol Med (Maywood) | Nonalcoholic fatty liver disease: update on pathogenesis, diagnosis, treatment and the role of S-adenosylmethionine. | 2015 | Details |
| A20726 | 25774446 | Curr Opin Gastroenterol | Nonalcoholic fatty liver disease: new treatments. | 2015 | Details |
| A20833 | 25705637 | Ann Transl Med | Recent advances in the development of farnesoid X receptor agonists. | 2015 | Details |
| A21235 | 25468160 | Lancet | Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. | 2014 | Details |
| A21343 | 25388536 | Curr Top Med Chem | Knocking on FXR's door: the "hammerhead"-structure series of FXR agonists - amphiphilic isoxazoles with potent in vitro and in vivo activities. | 2014 | Details |
| A22533 | 24486698 | Mol Cell Endocrinol | Nonalcoholic steatohepatitis as a novel player in metabolic syndrome-induced erectile dysfunction: an experimental study in the rabbit. | 2014 | Details |
| A23496 | 23727264 | Gastroenterology | Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease. | 2013 | Details |
| A24647 | 22652341 | Drug Discov Today | Farnesoid X receptor targeting to treat nonalcoholic steatohepatitis. | 2012 | Details |
| A28625 | 35217809 | Acta Pharmacol Sin | FXR: structures, biology, and drug development for NASH and fibrosis diseases. | 2022 | Details |
| A28715 | 35102596 | Hepatology | Discovery of a INSIG binding compound that ameliorates nonalcoholic steatohepatitis by inhibiting SREBP-mediated lipogenesis. | 2022 | Details |
| A29306 | 34274514 | Clin Gastroenterol Hepatol | Obeticholic Acid Impact on Quality of Life in Patients With Nonalcoholic Steatohepatitis: REGENERATE 18-Month Interim Analysis. | 2021 | Details |
| A29320 | 34256254 | Bioorg Med Chem | Discovery of novel ketoxime ether derivatives with potent FXR agonistic activity, oral effectiveness and high liver/blood ratio. | 2021 | Details |
| A29394 | 34149876 | Exp Ther Med | Co-administration of obeticholic acid and simvastatin protects against high-fat diet-induced non-alcoholic steatohepatitis in mice. | 2021 | Details |
| A30277 | 32712104 | Gastroenterology | FXR Isoforms Control Different Metabolic Functions in Liver Cells via Binding to Specific DNA Motifs. | 2020 | Details |
| A30480 | 32377219 | Nutr Metab (Lond) | Gypenosides regulate farnesoid X receptor-mediated bile acid and lipid metabolism in a mouse model of non-alcoholic steatohepatitis. | 2020 | Details |
| A30550 | 32247663 | Pharmacol Ther | Novel insights into the organic solute transporter alpha/beta, OSTα/β: From the bench to the bedside. | 2020 | Details |
| A30600 | 32140108 | Front Pharmacol | Corrigendum: Progression and Regression of Hepatic Lesions in a Mouse Model of NASH Induced by Dietary Intervention and Its Implications in Pharmacotherapy. | 2020 | Details |
| A30762 | 31832568 | Hepatol Commun | A Pilot Genome-Wide Analysis Study Identifies Loci Associated With Response to Obeticholic Acid in Patients With NASH. | 2019 | Details |
| A31019 | 31388629 | Hepatol Commun | Tropifexor-Mediated Abrogation of Steatohepatitis and Fibrosis Is Associated With the Antioxidative Gene Expression Profile in Rodents. | 2019 | Details |
| A31100 | 31227742 | Sci Rep | Combined obeticholic acid and elafibranor treatment promotes additive liver histological improvements in a diet-induced ob/ob mouse model of biopsy-confirmed NASH. | 2019 | Details |
| A31126 | 31201552 | Handb Exp Pharmacol | Obeticholic Acid: An Update of Its Pharmacological Activities in Liver Disorders. | 2019 | Details |
| A31144 | 31177586 | Hepatol Res | Combined effect of a farnesoid X receptor agonist and dipeptidyl peptidase-4 inhibitor on hepatic fibrosis. | 2019 | Details |
| A31444 | 30556039 | Hepatol Commun | Obeticholic Acid Modulates Serum Metabolites and Gene Signatures Characteristic of Human NASH and Attenuates Inflammation and Fibrosis Progression in Ldlr-/-.Leiden Mice. | 2018 | Details |
| A31513 | 30411084 | Hepatol Commun | FXR and TGR5 Agonists Ameliorate Liver Injury, Steatosis, and Inflammation After Binge or Prolonged Alcohol Feeding in Mice. | 2018 | Details |
| A31571 | 30271738 | J Clin Transl Hepatol | Future Pharmacotherapy for Non-alcoholic Steatohepatitis (NASH): Review of Phase 2 and 3 Trials. | 2018 | Details |
| A31816 | 29765319 | Front Pharmacol | Progression and Regression of Hepatic Lesions in a Mouse Model of NASH Induced by Dietary Intervention and Its Implications in Pharmacotherapy. | 2018 | Details |
| A32073 | 29259742 | ACS Med Chem Lett | Synthesis and Biological Evaluation of a Series of Bile Acid Derivatives as FXR Agonists for Treatment of NASH. | 2017 | Details |
| A32305 | 31966664 | Int J Clin Exp Pathol | Obeticholic acid improves hepatic steatosis and inflammation by inhibiting NLRP3 inflammasome activation. | 2017 | Details |
| A32667 | 27804232 | Obesity (Silver Spring) | Obeticholic acid improves adipose morphometry and inflammation and reduces steatosis in dietary but not metabolic obesity in mice. | 2016 | Details |
| A33468 | 25926979 | F1000Prime Rep | Recent advances in understanding/management of non-alcoholic steatohepatitis. | 2015 | Details |
| A42318 | 34886776 | Curr Vasc Pharmacol | Cilofexor for the Treatment of Nonalcoholic Steatohepatitis | 2022 | Details |
| A42505 | 34345273 | Exp Ther Med | Obeticholic acid ameliorates obesity and hepatic steatosis by activating brown fat. | 2021 | Details |
| A42623 | 33985820 | J Hepatol | FXR agonists for NASH: How are they different and what difference do they make? | 2021 | Details |
| A42755 | 33568795 | Nat Rev Gastroenterol Hepatol | The role of farnesoid X receptor in metabolic diseases, and gastrointestinal and liver cancer. | 2021 | Details |
| A43290 | 32050066 | J Chem Inf Model | Pose Filter-Based Ensemble Learning Enables Discovery of Orally Active, Nonsteroidal Farnesoid X Receptor Agonists. | 2020 | Details |
| A43316 | 31986920 | Expert Opin Investig Drugs | Fatty liver disease and primary liver cancer: disease mechanisms, emerging therapies and the role of bariatric surgery. | 2020 | Details |
| A43317 | 31985310 | Expert Opin Investig Drugs | Prof Jörn Schattenberg sheds light on key treatment and diagnostic approaches to nonalcoholic steatohepatitis (NASH). | 2020 | Details |
| A43318 | 31984804 | Expert Opin Investig Drugs | NASH and NAFLD: emerging drugs, therapeutic targets and translational and clinical challenges. | 2020 | Details |
| A43337 | 31971024 | Expert Opin Investig Drugs | Nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): prevalence, therapeutic innovations, and stumbling blocks for clinical development. | 2020 | Details |
| A43348 | 31930974 | Metabolism | Obeticholic acid for the treatment of nonalcoholic steatohepatitis: Expectations and concerns. | 2020 | Details |
| A43404 | 31813639 | Lancet | Obeticholic acid: towards first approval for NASH. | 2019 | Details |
| A43639 | 31237448 | Am J Physiol Endocrinol Metab | Obeticholic acid ameliorates dyslipidemia but not glucose tolerance in mouse model of gestational diabetes. | 2019 | Details |
| A44174 | 29512910 | Aliment Pharmacol Ther | Editorial: weight change, liver histology and the metabolic effects of obeticholic acid in NASH. | 2018 | Details |
| A44410 | 28692197 | J Gastroenterol Hepatol | The Asia-Pacific Working Party on Non-alcoholic Fatty Liver Disease guidelines 2017-Part 2: Management and special groups. | 2018 | Details |
| A44547 | 28277800 | Expert Rev Clin Pharmacol | Emerging therapies for NASH - the future is now. | 2017 | Details |
| A45071 | 26169862 | Lancet | Trials of obeticholic acid for non-alcoholic steatohepatitis. | 2015 | Details |
| A45072 | 26169861 | Lancet | Trials of obeticholic acid for non-alcoholic steatohepatitis - Authors' reply. | 2015 | Details |
| A45073 | 26169860 | Lancet | Trials of obeticholic acid for non-alcoholic steatohepatitis. | 2015 | Details |
| A45158 | 25864227 | Ann Hepatol | Obeticholic acid: expanding the therapeutic landscape of NASH. | 2016 | Details |
| A45193 | 25753820 | Hepatology | Obeticholic acid and resveratrol in nonalcoholic fatty liver disease: all that is gold does not glitter, not all those who wander are lost. | 2015 | Details |
| A45197 | 25726736 | Gastroenterology | Is obeticholic Acid the solution to nonalcoholic steatohepatitis? | 2015 | Details |
| A45279 | 25421586 | Nat Rev Gastroenterol Hepatol | NAFLD: obeticholic acid for the treatment of fatty liver disease--NASH no more? | 2014 | Details |
| A46951 | 32879433 | Commun Biol | Oxidation of fish oil exacerbates alcoholic liver disease by enhancing intestinal dysbiosis in mice. | 2020 | Details |
| A47646 | 34386202 | Clin Liver Dis (Hoboken) | Obeticholic Acid for the Treatment of Nonalcoholic Steatohepatitis. | 2021 | Details |
| A47746 | 32597707 | Am J Physiol Gastrointest Liver Physiol | Obeticholic acid improves fetal bile acid profile in a mouse model of gestational hypercholanemia. | 2020 | Details |
| A47948 | 28542140 | Cell Death Dis | miR-21 ablation and obeticholic acid ameliorate nonalcoholic steatohepatitis in mice. | 2017 | Details |
| A47982 | 27425465 | J Steroid Biochem Mol Biol | Cardiopulmonary protective effects of the selective FXR agonist obeticholic acid in the rat model of monocrotaline-induced pulmonary hypertension. | 2016 | Details |
| A48003 | 26811456 | Proc Natl Acad Sci U S A | Obeticholic acid, a synthetic bile acid agonist of the farnesoid X receptor, attenuates experimental autoimmune encephalomyelitis. | 2016 | Details |
| A48060 | 25388535 | Curr Top Med Chem | Bile acid derivatives as ligands of the farnesoid x receptor: molecular determinants for bile acid binding and receptor modulation. | 2014 | Details |
| A48652 | 32329946 | Liver Int | A novel non-bile acid FXR agonist EDP-305 potently suppresses liver injury and fibrosis without worsening of ductular reaction. | 2020 | Details |
| A48656 | 32195457 | JHEP Rep | miR-22 inhibition reduces hepatic steatosis via FGF21 and FGFR1 induction. | 2020 | Details |
| A48660 | 32064266 | Front Med (Lausanne) | Bile Acid Receptor Therapeutics Effects on Chronic Liver Diseases. | 2020 | Details |
| A48743 | 30026040 | Bioorg Med Chem | Structural optimization and in vitro profiling of N-phenylbenzamide-based farnesoid X receptor antagonists. | 2018 | Details |